Alterity Therapeutics Ltd - Asset Resilience Ratio
Alterity Therapeutics Ltd (ATH) has an Asset Resilience Ratio of 86.44% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Alterity Therapeutics Ltd (ATH) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how Alterity Therapeutics Ltd's Asset Resilience Ratio has changed over time. See net asset quality index of Alterity Therapeutics Ltd to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Alterity Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Alterity Therapeutics Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$49.20 Million | 86.44% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$49.20 Million | 86.44% |
Asset Resilience Insights
- Very High Liquidity: Alterity Therapeutics Ltd maintains exceptional liquid asset reserves at 86.44% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Alterity Therapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare Alterity Therapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Hugel Inc
KQ:145020 |
Biotechnology | 29.57% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 39.07% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Absci Corp
NASDAQ:ABSI |
Biotechnology | 59.86% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
Annual Asset Resilience Ratio for Alterity Therapeutics Ltd (2006–2025)
The table below shows the annual Asset Resilience Ratio data for Alterity Therapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 16.30% | AU$7.50 Million ≈ $5.31 Million |
AU$46.03 Million ≈ $32.57 Million |
-- |
| 2024-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$19.22 Million ≈ $13.60 Million |
-- |
| 2022-06-30 | 84.15% | AU$34.81 Million ≈ $24.63 Million |
AU$41.36 Million ≈ $29.27 Million |
+0.44pp |
| 2021-06-30 | 83.71% | AU$28.12 Million ≈ $19.89 Million |
AU$33.59 Million ≈ $23.76 Million |
+82.26pp |
| 2020-06-30 | 1.45% | AU$192.71K ≈ $136.35K |
AU$13.30 Million ≈ $9.41 Million |
-70.88pp |
| 2019-06-30 | 72.33% | AU$14.40 Million ≈ $10.19 Million |
AU$19.91 Million ≈ $14.09 Million |
-9.09pp |
| 2018-06-30 | 81.41% | AU$15.25 Million ≈ $10.79 Million |
AU$18.73 Million ≈ $13.25 Million |
-5.33pp |
| 2017-06-30 | 86.74% | AU$21.93 Million ≈ $15.52 Million |
AU$25.28 Million ≈ $17.89 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$33.73 Million ≈ $23.86 Million |
-- |
| 2015-06-30 | 0.36% | AU$152.60K ≈ $107.98K |
AU$41.83 Million ≈ $29.60 Million |
-0.23pp |
| 2007-06-30 | 0.59% | AU$45.63K ≈ $32.28K |
AU$7.72 Million ≈ $5.46 Million |
+0.18pp |
| 2006-06-30 | 0.41% | AU$42.40K ≈ $30.00K |
AU$10.43 Million ≈ $7.38 Million |
-- |
About Alterity Therapeutics Ltd
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more